Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07539623 · ClinicalTrials.gov registry record · Phase 3
Suzetrigine-enhanced MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery
A Phase 3 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 235
- Enrollment target
NCT07539623 is a Phase 3 study that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 235 participants.
The verdict
NCT07539623, a Phase 3 study, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 235 participants
- Enrollment target
Study Summary
This is prospective, randomized study. The purpose of this study is to evaluate whether the addition of Suzetrigine to well established multimodal pain regimen for participants undergoing bariatric patients undergoing weight-loss surgery and cardiac patients undergoing sternotomy will reduce post-operative opioid consumption and pain scores.
Interventions
- DRUG Placebo
- DRUG Suzetrigine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 235 participants |
| Start Date | 2026-05-01 |
| Est. Completion | 2026-12-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07539623
The ClinicalTrials.gov registry entry for NCT07539623 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 235 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07539623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07539623 about?
NCT07539623 is a clinical study titled "Suzetrigine-enhanced MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery". This is prospective, randomized study. The purpose of this study is to evaluate whether the addition of Suzetrigine to well established multimodal pain regimen for participants undergoing bariatric patients undergoing weight-loss surgery and cardiac patients undergoing sternotomy will reduce post-op...
What is the current status of trial NCT07539623?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 235 participants. The study started on 2026-05-01. Estimated completion is 2026-12-22.
What interventions are being tested in trial NCT07539623?
The interventions under investigation include: Placebo (DRUG), Suzetrigine (DRUG).
Who is sponsoring clinical trial NCT07539623?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.